News2020-01-13T19:53:06+00:00

NEWS 

704, 2022

GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO

Categories: Press Coverage, Uncategorized|

NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (“GABA”) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (“atai”) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer [...]

210, 2021

GABA Therapeutics Completes Single Ascending Dose (SAD) Stage of Phase 1 Study in GRX-917 in Melbourne

Categories: Press Coverage, Uncategorized|

NEWPORT BEACH, CA – GABA Therapeutics, Inc has successfully completed the single ascending dose (SAD) stage of its Phase 1 study of GRX-917 in Melbourne, Australia. Interim data from the SAD stage showed that GRX-917 was well tolerated and favorable safety results were observed up to 500mg. Furthermore, the results [...]

406, 2020

GABA Therapeutics Completed Phase 1 Etifoxine in Melbourne

Categories: Press Coverage, Uncategorized|

GABA Therapeutics has continued to progress the development of GRX-917 without any material impact from the COVID-19 pandemic. GABA Therapeutics recently completed its Phase 1 clinical trial of the anxiolytic etifoxine in Melbourne, Australia, on time and slightly ahead of budget. The two-stage, double-blind, placebo-controlled single and multiple dose [...]

2402, 2020

Biotech with Anxiety Drug Lands Funding

Categories: Press Coverage, Uncategorized|Tags: , , |

DRUGS: $15.5M; XANAX IMPROVEMENT? Biotech with Anxiety Drug Lands Funding By Jessie Yount Orange Country Business Journal Monday, February 24, 2020 An effort to develop a new and improved version of an anti-anxiety drug—never commercialized in the U.S.—is underway in Newport Beach. Gaba Therapeutics Inc. has developed and patented a [...]

1401, 2020

GABA Therapeutics Commences Phase I Study in Etifoxine – Melbourne Australia

Categories: Press Coverage, Uncategorized|

Today, GABA Therapeutics commenced dosing for its Phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia – right on schedule. The Phase I, two-stage, double-blind, placebo-controlled single and multiple dose study will evaluate the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy [...]

2711, 2019

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

Categories: Press Coverage, Uncategorized|

We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]